Alectinib

Herden, M.; Waller, Christiane

doi:10.1007/978-3-319-91442-8_17

Cited by 16 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALK mutations, especially rearrangements, exhibit strong translational activity in NSCLC [ 81 ]. ALK-targeted agents such as alectinib [ 82 ] and brigatinib [ 83 ] have shown extraordinary efficacy in ALK-positive NSCLC and have become the first-line therapies [ 84 ]. Lorlatinib, an ALK inhibitor [ 85 ], appears as a burst word in 2020, and ALK-TKI and ALK rearrangement have a high weight from 2019 to 2020 ( Figure 3 ), both of which indicate the rapidly rising attention on ALK.…”

Section: Discussionmentioning

confidence: 99%

Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study

Hu¹,

Xing²,

Zhang³

et al. 2022

JMIR Med Inform

View full text Add to dashboard Cite

Background Tyrosine kinase inhibitors (TKIs) have achieved revolutionary results in the treatment of a wide range of tumors, and many studies on this topic continue to be published every year. Some of the published reviews provide great value for us to understand TKIs. However, there is a lack of studies on the knowledge structure, bibliometric analysis, and visualization results in TKIs research. Objective This paper aims to investigate the knowledge structure, hotspots, and trends of evolution of the TKIs research by co-word analysis and literature visualization and help researchers in this field to gain a comprehensive understanding of the current status and trends. Methods We retrieved all academic papers about TKIs published between 2016 and 2020 from the Web of Science. By counting keywords from those papers, we generated the co-word networks by extracting the co-occurrence relationships between keywords, and then segmented communities to identify the subdirections of TKIs research by calculating the network metrics of the overall and local networks. We also mapped the association network topology, including the network within and between TKIs subdirections, to reveal the association and structure among varied subdirections. Furthermore, we detected keyword bursts by combining their burst weights and durations to reveal changes in the focus of TKIs research. Finally, evolution venation and strategic diagram were generated to reveal the trends of TKIs research. Results We obtained 6782 unique words (total frequency 26,175) from 5584 paper titles. Finally, 296 high-frequency words were selected with a threshold of 10 after discussion, the total frequency of which accounted for 65.41% (17,120/26,175). The analysis of burst disciplines revealed a variable number of burst words of TKIs research every year, especially in 2019 and 2020, such as HER2, pyrotinib, next-generation sequencing, immunotherapy, ALK-TKI, ALK rearrangement. By network calculation, the TKIs co-word network was divided into 6 communities: C1 (non-small–cell lung cancer), C2 (targeted therapy), C3 (chronic myeloid leukemia), C4 (HER2), C5 (pharmacokinetics), and C6 (ALK). The venation diagram revealed several clear and continuous evolution trends, such as non-small–cell lung cancer venation, chronic myeloid leukemia venation, renal cell carcinoma venation, chronic lymphocytic leukemia venation. In the strategic diagram, C1 (non-small–cell lung cancer) was the core direction located in the first quadrant, C2 (targeted therapy) was exactly at the junction of the first and fourth quadrants, which meant that C2 was developing; and C3 (chronic myeloid leukemia), C4 (HER2), and C5 (pharmacokinetics) were all immature and located in the third quadrant. Conclusions Using co-word analysis and literature visualization, we revealed the hotspots, knowledge structure, and trends of evolution of TKIs research between 2016 and 2020. TKIs research mainly focused on targeted therapies against varied tumors, particularly against non-small–cell lung cancer. The attention on chronic myeloid leukemia and pharmacokinetics was gradually decreasing, but the focus on HER2 and ALK was rapidly increasing. TKIs research had shown a clear development path: TKIs research was disease focused and revolved around “gene targets/targeted drugs/resistance mechanisms.” Our outcomes will provide sound and effective support to researchers, funders, policymakers, and clinicians.

show abstract

Section: Discussionmentioning

confidence: 99%

Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study

Hu¹,

Xing²,

Zhang³

et al. 2022

JMIR Med Inform

View full text Add to dashboard Cite

show abstract

“…In our case, tubular injury was the predominant manifestation, but the severity was lower than reported by Ramachandran et al Alectinib is an ATP-competitive small molecule, which has improved the progression free survival in ALK positive NCLSC through the inhibition of ALK and RET protein phosphorylation thus disrupting downstream signalling of cell proliferation. 10 11 . Whether this ability to inhibit cell proliferation signalling may also affect renal tubular cells to result in tubular injury is unclear but could be a possible explanatory mechanism.…”

Section: Discussionmentioning

confidence: 99%

Acute kidney Injury due to Alectinib, an Anaplastic Lymphoma Kinase inhibitor

Abdalla

Galambosi

et al. 2021

Journal of Onco-Nephrology

View full text Add to dashboard Cite

Introduction: The array of unintended effects of targeted oncological treatments is still being elucidated. Cognizance of these effects is important since they allow early identification and intervention. Methods: We report a case of progressive reduction in kidney function following the introduction of the oral second generation Anaplastic Lymphoma Kinase (ALK) Inhibitor: Alectinib for the treatment of metastatic non-small cell carcinoma of the lung (NSCLC). Kidney biopsy findings suggested that the predominant manifestation was acute tubular injury, which resolved with cessation of Alectinib therapy and did not recur with the introduction of the third generation ALK inhibitor Lorlatinib. Conclusions: This case report adds to the Onco-Nephrology literature in relation to the potential nephrotoxic effects of ALK inhibitors.

show abstract

“…Since HCoV-OC43, as other coronaviruses, is able to invade the CNS (Dubé et al, 2018), alectinib might be an interesting candidate for the treatment of HCoV-OC43 persistent infections in the brain. Moreover, the free levels of alectinib found in both plasma and cerebrospinal fluid are similar (Herden & Waller, 2018) and its EC 50 against HCoV-OC43 (0.6 uM) is lower than the maximum level attainable in human serum with daily recommended dosage (676 ng/mL corresponding to 1.4 μM) (Ly et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Combinedin silicodocking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors

Milani

Donalisio

Bonotto

et al. 2020

Preprint

View full text Add to dashboard Cite

The current emergency of the novel coronavirus SARS-CoV-2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a pipeline based on in silico docking of known drugs on SARS-CoV RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS-CoV-2 and the common cold human coronavirus HCoV-OC43. Results showed that certain drugs displayed activity for both viruses at a similar inhibitory concentration, while others were specific. In particular, the antipsychotic drug lurasidone and the antiviral drug elbasvir showed promising activity in the low micromolar range against both viruses with good selective index.

show abstract

Alectinib

Cited by 16 publications

References 30 publications

Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study

Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study

Acute kidney Injury due to Alectinib, an Anaplastic Lymphoma Kinase inhibitor

Combinedin silicodocking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors

Contact Info

Product

Resources

About